JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
Atorvastatin as an Add-on Therapy in Episodic Migraine Prophylaxis: A Randomised Controlled Study
Introduction: Migraine is a primary headache disorder with an estimated frequency of 12% in the world population, ranked fifth among causes of disability worldwide in both sexes under 50 years. Conventional prophylactic agents are limited by adverse effects and poor tolerability. Atorvastatin, a HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor with pleiotropic anti-inflammatory and endothelial-protective properties, has been proposed as a potential prophylactic agent in migraine. Aim: To assess t …